FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147888544> ?p ?o ?g. }

• W2147888544 endingPage "15" @default.
• W2147888544 startingPage "7" @default.
• W2147888544 abstract "The traditional assumption of a linear relationship between serum testosterone and prostate cancer growth has been seriously challenged, as overwhelming evidence contradicts its basic principles. Luteinizing hormone–releasing hormone (LHRH) agonists are known to cause a peak in serum testosterone level in the initial weeks of treatment, and prevention of the clinical sequelae of testosterone flare by concomitant use of antiandrogens is recommended. Along the present biological concept that there appears to be a limit to the ability of androgens to stimulate prostate cancer growth, termed the saturation model, the use of antiandrogens to prevent this disease flare is questioned. The purpose of this review is to gain historical and modern evidence to provide an objective and up-to-date basis for clinical decision making. We performed a comprehensive research of the electronic databases PubMed and Embase until April 1, 2014. Studies with the subject of disease flare in men with prostate cancer on LHRH agonist therapy were included, as were studies that assessed the efficacy of antiandrogens to prevent this flare. Case reports were included as well. Overall, 25 studies considering disease flare were included: 9 randomized clinical trials with an LHRH agonist and an LHRH agonist/antiandrogen arm, 14 observational studies evaluating LHRH agonists only, and 2 case reports. The incidence of disease flare was reported between 0% and 83% owing to a wide set of clinical, biochemical, and radiological factors evaluated. In some of the randomized clinical trials, a statistically significant reduction of the incidence of disease flare by concomitant use of antiandrogens was reported. Most of these historical studies report on subjective worsening of disease symptoms as outcome measure. More objective outcome measures such as the prostate-specific antigen level did not seem to increase to higher than the baseline values. At present, there is a lack of compelling data showing definite disease progression during the short period of testosterone flare after initiation of LHRH agonist therapy. Based on the saturation model, presence of disease flare and the need to prevent this flare by concomitant use of antiandrogens might well be a misconception." @default.
• W2147888544 created "2016-06-24" @default.
• W2147888544 creator A5025890613 @default.
• W2147888544 creator A5037691698 @default.
• W2147888544 creator A5052727970 @default.
• W2147888544 creator A5056426178 @default.
• W2147888544 creator A5086355643 @default.
• W2147888544 date "2015-01-01" @default.
• W2147888544 modified "2023-10-16" @default.
• W2147888544 title "Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?" @default.
• W2147888544 cites W1576421572 @default.
• W2147888544 cites W1582959126 @default.
• W2147888544 cites W1976303302 @default.
• W2147888544 cites W1989996812 @default.
• W2147888544 cites W1991022119 @default.
• W2147888544 cites W1992811319 @default.
• W2147888544 cites W1993071730 @default.
• W2147888544 cites W1996418118 @default.
• W2147888544 cites W1997807118 @default.
• W2147888544 cites W2014145760 @default.
• W2147888544 cites W2014241088 @default.
• W2147888544 cites W2015024838 @default.
• W2147888544 cites W2016016099 @default.
• W2147888544 cites W2016747974 @default.
• W2147888544 cites W2022008209 @default.
• W2147888544 cites W2034835400 @default.
• W2147888544 cites W2040997484 @default.
• W2147888544 cites W2044266924 @default.
• W2147888544 cites W2044753744 @default.
• W2147888544 cites W2046984746 @default.
• W2147888544 cites W2057741532 @default.
• W2147888544 cites W2060991243 @default.
• W2147888544 cites W2069109889 @default.
• W2147888544 cites W2075118988 @default.
• W2147888544 cites W2088140811 @default.
• W2147888544 cites W2092411321 @default.
• W2147888544 cites W2094386924 @default.
• W2147888544 cites W2103687167 @default.
• W2147888544 cites W2105922775 @default.
• W2147888544 cites W2108040669 @default.
• W2147888544 cites W2109494488 @default.
• W2147888544 cites W2114770772 @default.
• W2147888544 cites W2122428351 @default.
• W2147888544 cites W2125808391 @default.
• W2147888544 cites W2128343224 @default.
• W2147888544 cites W2128803757 @default.
• W2147888544 cites W2132322310 @default.
• W2147888544 cites W2133467178 @default.
• W2147888544 cites W2139625866 @default.
• W2147888544 cites W2149217977 @default.
• W2147888544 cites W2226127019 @default.
• W2147888544 cites W2276902499 @default.
• W2147888544 cites W2326289669 @default.
• W2147888544 cites W2405844923 @default.
• W2147888544 cites W2426149359 @default.
• W2147888544 cites W28682465 @default.
• W2147888544 cites W4235935036 @default.
• W2147888544 cites W4247340796 @default.
• W2147888544 cites W4253882649 @default.
• W2147888544 cites W4293409513 @default.
• W2147888544 cites W4321429490 @default.
• W2147888544 cites W4376453286 @default.
• W2147888544 cites W75430235 @default.
• W2147888544 doi "https://doi.org/10.1016/j.urolonc.2014.04.016" @default.
• W2147888544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25159013" @default.
• W2147888544 hasPublicationYear "2015" @default.
• W2147888544 type Work @default.
• W2147888544 sameAs 2147888544 @default.
• W2147888544 citedByCount "15" @default.
• W2147888544 countsByYear W21478885442016 @default.
• W2147888544 countsByYear W21478885442018 @default.
• W2147888544 countsByYear W21478885442019 @default.
• W2147888544 countsByYear W21478885442020 @default.
• W2147888544 countsByYear W21478885442021 @default.
• W2147888544 countsByYear W21478885442022 @default.
• W2147888544 countsByYear W21478885442023 @default.
• W2147888544 crossrefType "journal-article" @default.
• W2147888544 hasAuthorship W2147888544A5025890613 @default.
• W2147888544 hasAuthorship W2147888544A5037691698 @default.
• W2147888544 hasAuthorship W2147888544A5052727970 @default.
• W2147888544 hasAuthorship W2147888544A5056426178 @default.
• W2147888544 hasAuthorship W2147888544A5086355643 @default.
• W2147888544 hasConcept C121608353 @default.
• W2147888544 hasConcept C126322002 @default.
• W2147888544 hasConcept C134018914 @default.
• W2147888544 hasConcept C143998085 @default.
• W2147888544 hasConcept C2778575703 @default.
• W2147888544 hasConcept C2778894405 @default.
• W2147888544 hasConcept C2779093440 @default.
• W2147888544 hasConcept C2779279991 @default.
• W2147888544 hasConcept C2779322244 @default.
• W2147888544 hasConcept C2780192828 @default.
• W2147888544 hasConcept C2910016293 @default.
• W2147888544 hasConcept C29456083 @default.
• W2147888544 hasConcept C71315377 @default.
• W2147888544 hasConcept C71924100 @default.
• W2147888544 hasConceptScore W2147888544C121608353 @default.
• W2147888544 hasConceptScore W2147888544C126322002 @default.

• next